INT7682

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1986
Last Reported 2010
Negated 2
Speculated 1
Reported most in Abstract
Documents 22
Total Number 23
Disease Relevance 1.80
Pain Relevance 11.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (Drd1a) plasma membrane (Drd1a) nucleus (Drd1a)
intracellular (Drd1a) signal transducer activity (Drd1a)
Anatomy Link Frequency
striatum 2
substantia nigra 2
entopeduncular nucleus 1
shell 1
outflow 1
Drd1a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Dopamine 369 100.00 Very High Very High Very High
agonist 112 100.00 Very High Very High Very High
Enkephalin 5 100.00 Very High Very High Very High
substance P 3 100.00 Very High Very High Very High
dopamine receptor 66 99.96 Very High Very High Very High
noradrenaline 5 99.84 Very High Very High Very High
Glutamate 14 99.80 Very High Very High Very High
nMDA receptor 11 99.80 Very High Very High Very High
antagonist 66 99.64 Very High Very High Very High
Opioid 5 99.64 Very High Very High Very High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 90 99.82 Very High Very High Very High
Nociception 2 88.32 High High
Drug Dependence 10 86.08 High High
Disease 84 82.28 Quite High
Cognitive Disorder 34 76.32 Quite High
Stress 21 75.00 Quite High
Generalized Anxiety Disorder 2 73.60 Quite High
INFLAMMATION 1 62.36 Quite High
Paralysis 1 57.60 Quite High
Respiratory Failure 1 47.68 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain.
dopamine D1 receptor Binding (binding) of in brain associated with dopamine and anesthesia
1) Confidence 0.48 Published 2004 Journal Synapse Section Title Doc Link 15476291 Disease Relevance 0 Pain Relevance 0.74
Dopamine D-1 receptor binding increased significantly in the accumbens core and shell.
Dopamine D-1 receptor Binding (binding) of in shell associated with dopamine
2) Confidence 0.42 Published 2001 Journal Neuroreport Section Abstract Doc Link 11733709 Disease Relevance 0.09 Pain Relevance 0.42
Dual label immunofluorescence by means of confocal microscopy was used to detect the presence of huntingtin among striatal projection neurons identified by their cellular content of Substance P, Enkephalin, CB1 receptor, and D1a dopamine receptor.
D1a Binding (content) of in projection neurons associated with dopamine receptor, enkephalin, projection neuron and substance p
3) Confidence 0.36 Published 2003 Journal Neurosci. Lett. Section Abstract Doc Link 12618299 Disease Relevance 0.22 Pain Relevance 0.25
Whereas the spontaneous outflow of SPLM and CGRPLM was changed by none of the agonists/antagonists of monoamine receptors tested, the overflow of both peptide-like materials due to 30 mM K+ was differentially affected by alpha 2-adrenoreceptor and dopamine D-1 receptor ligands.
dopamine D-1 receptor Binding (ligands) of in outflow associated with dopamine, antagonist, agonist and monoamine
4) Confidence 0.35 Published 1993 Journal Neuropharmacology Section Abstract Doc Link 7689707 Disease Relevance 0 Pain Relevance 0.68
No changes in dopamine D1 receptor binding were observed in any group.
dopamine D1 receptor Binding (binding) of associated with dopamine
5) Confidence 0.34 Published 2004 Journal Neuroscience Section Abstract Doc Link 14980394 Disease Relevance 0.26 Pain Relevance 0.52
Remoxipride did not block dopamine-stimulated adenylate cyclase activity in vitro suggesting that it did not directly interact with the dopamine D1 receptor.
dopamine D1 receptor Neg (not) Binding (interact) of associated with dopamine
6) Confidence 0.33 Published 1990 Journal Acta Psychiatr Scand Suppl Section Abstract Doc Link 1978484 Disease Relevance 0 Pain Relevance 0.37
SKF 38393-induced circling was selectively blocked by the specific D-1 antagonists SCH 23390 and SKF 83566, and was furthermore blocked by other DA antagonists with potencies correlating to their affinities to D-1 receptors labelled by 3H-SCH 23390 in vitro.
D-1 Binding (affinities) of associated with dopamine and antagonist
7) Confidence 0.31 Published 1986 Journal J. Neural Transm. Section Abstract Doc Link 2949056 Disease Relevance 0 Pain Relevance 0.64
No interaction between D-1 and D-2 antagonists was observed in combination experiments with SCH 23390 and YM 09151-2 in both circling models.
D-1 Neg (No) Binding (interaction) of associated with antagonist
8) Confidence 0.31 Published 1986 Journal J. Neural Transm. Section Abstract Doc Link 2949056 Disease Relevance 0 Pain Relevance 0.82
Here we describe the potent antinociceptive action of the indolophenanthridine, CY 208-243, which has high affinities to the dopamine D1 binding and the opioid sites as well as to the 5-HT1A site.
dopamine D1 Binding (binding) of associated with dopamine, opioid and antinociceptive
9) Confidence 0.30 Published 1988 Journal Life Sci. Section Abstract Doc Link 2826954 Disease Relevance 0.15 Pain Relevance 0.79
Quantitative autoradiography of receptor binding sites revealed only a significant reduction of [3H]SCH-23390 and [3H]spiperone binding to D-1 and D-2 sites, respectively, in the substantia nigra pars compacta of morphine-treated rats. 5-HT and 5-HIAA levels remained unchanged in the substantia nigra and striatum, but the nigral levels of DA and DOPAC and the levels of DOPAC in the striatum were reduced significantly by morphine treatment.
D-1 Binding (binding) of in striatum associated with dopamine, substantia nigra and morphine
10) Confidence 0.28 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2456939 Disease Relevance 0 Pain Relevance 0.86
Several lines of evidence have suggested there may be a physiologically relevant form of synergistic interaction between D-1 and D-2 dopamine (DA) receptors located on postsynaptic neurons in the forebrain that receive a dopaminergic innervation.
D-1 Binding (interaction) of in forebrain associated with dopamine
11) Confidence 0.26 Published 1992 Journal Synapse Section Abstract Doc Link 1354398 Disease Relevance 0.06 Pain Relevance 0.20
Synergistic interaction between dopamine D-1 and D-2 receptor agonists: circling behaviour of rats with hemitransection.
dopamine D-1 Binding (interaction) of associated with dopamine and agonist
12) Confidence 0.25 Published 1987 Journal Eur. J. Pharmacol. Section Title Doc Link 3500865 Disease Relevance 0 Pain Relevance 0.37
The interaction of agonist compounds with the D1 receptor appeared to be more complex.
D1 receptor Spec (appeared) Binding (interaction) of associated with agonist
13) Confidence 0.24 Published 1992 Journal Neuropharmacology Section Abstract Doc Link 1532443 Disease Relevance 0 Pain Relevance 0.62
Given the complex interactions between dopamine D1 and glutamate NMDA receptors in the striatum, we investigated the role of these receptors in transporter-mediated GABA release from cultured medium spiny neurons of rat striatum.
dopamine D1 Binding (interactions) of in striatum associated with gaba, glutamate, dopamine and nmda receptor
14) Confidence 0.22 Published 2000 Journal J. Neurosci. Section Abstract Doc Link 10777812 Disease Relevance 0 Pain Relevance 0.57
Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.
dopamine D1 Binding (interacting) of in neurons associated with gaba, dopamine and nmda receptor
15) Confidence 0.22 Published 2000 Journal J. Neurosci. Section Title Doc Link 10777812 Disease Relevance 0 Pain Relevance 0.88
We report that curcumin supplementation reduces diabetes induced alteration of dopamine D1, D2 receptors, transcription factor CREB and phospholipase C to near control.
dopamine D1 Binding (alteration) of associated with dopamine and diabetes mellitus
16) Confidence 0.19 Published 2010 Journal J Biomed Sci Section Abstract Doc Link PMC2890658 Disease Relevance 0.80 Pain Relevance 0.45
In contrast to the uniform reduction in D2-receptor binding, fluphenazine altered D1-receptor binding in a region-dependent manner.
D1-receptor Binding (binding) of
17) Confidence 0.14 Published 1997 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 9387879 Disease Relevance 0.14 Pain Relevance 0.11
Moreover, in vitro radioligand binding assay demonstrated that SPD was able to bind to the D1 receptor at two sites, a high-affinity site (Ki = 3.9 nM) and a low-affinity site (Ki = 126 nM), using calf striatal membrane preparations [16].
D1 receptor Binding (bind) of
18) Confidence 0.10 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644490 Disease Relevance 0.08 Pain Relevance 0.56
Furthermore, binding experiments showed that SPD binds to the D1 receptor with high affinity (Ki = 13 nM, [76]), but exhibits much lower affinity for other receptors [35, 84].
D1 receptor Binding (binds) of
19) Confidence 0.10 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2644490 Disease Relevance 0 Pain Relevance 0.25
Quantitative autoradiography of receptor binding sites revealed only a significant reduction of [3H]SCH-23390 and [3H]spiperone binding to D-1 and D-2 sites, respectively, in the substantia nigra pars compacta of morphine-treated rats. 5-HT and 5-HIAA levels remained unchanged in the substantia nigra and striatum, but the nigral levels of DA and DOPAC and the levels of DOPAC in the striatum were reduced significantly by morphine treatment.
D-1 Binding (binding) of in substantia nigra associated with dopamine, substantia nigra and morphine
20) Confidence 0.09 Published 1988 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2456939 Disease Relevance 0 Pain Relevance 0.86

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox